As of June 24, 2025, Reliq Health Technologies Inc has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $0.21, this represents a potential upside of -1786897.8%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -37195.9% |
| Potential Upside (10-year) | -1786897.8% |
| Discount Rate (WACC) | 5.6% - 8.2% |
Revenue is projected to grow from $9 million in 06-2023 to $59216 million by 06-2033, representing a compound annual growth rate of approximately 140.9%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 06-2023 | 9 | 485% |
| 06-2024 | 9 | 6% |
| 06-2025 | 32 | 250% |
| 06-2026 | 109 | 245% |
| 06-2027 | 325 | 199% |
| 06-2028 | 907 | 179% |
| 06-2029 | 2369 | 161% |
| 06-2030 | 5769 | 144% |
| 06-2031 | 13211 | 129% |
| 06-2032 | 28662 | 117% |
| 06-2033 | 59216 | 107% |
Net profit margin is expected to improve from -96% in 06-2023 to -62% by 06-2033, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 06-2023 | (8) | -96% |
| 06-2024 | (6) | -68% |
| 06-2025 | (21) | -67% |
| 06-2026 | (72) | -66% |
| 06-2027 | (210) | -65% |
| 06-2028 | (576) | -63% |
| 06-2029 | (1,498) | -63% |
| 06-2030 | (3,637) | -63% |
| 06-2031 | (8,301) | -63% |
| 06-2032 | (17,950) | -63% |
| 06-2033 | (36,963) | -62% |
with a 5-year average of $0 million. Projected CapEx is expected to maintain at approximately 6% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 06-2024 | 0 |
| 06-2025 | 0 |
| 06-2026 | 2 |
| 06-2027 | 5 |
| 06-2028 | 15 |
| 06-2029 | 41 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 371 |
| Days Inventory | 257 |
| Days Payables | 156 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2024 | (8) | (2) | 0 | 4 | (10) |
| 2025 | (29) | (8) | 2 | 28 | (51) |
| 2026 | (98) | (27) | 6 | 73 | (150) |
| 2027 | (287) | (78) | 18 | 248 | (475) |
| 2028 | (786) | (213) | 50 | 636 | (1,260) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -37195.9% |
| 10-Year DCF (Growth) | 0.00 | -1786897.8% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Reliq Health Technologies Inc (RHT.V) a buy or a sell? Reliq Health Technologies Inc is definitely a sell. Based on our DCF analysis, Reliq Health Technologies Inc (RHT.V) appears to be overvalued with upside potential of -1786897.8%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $0.21.